KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Common Equity (2016 - 2026)

Pacific Biosciences Of California has reported Common Equity over the past 16 years, most recently at $5.3 million for Q4 2025.

  • For Q4 2025, Common Equity fell 98.94% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $5.3 million, down 98.94%, while the annual FY2025 figure was $5.3 million, 98.94% down from the prior year.
  • Common Equity for Q4 2025 was $5.3 million at Pacific Biosciences Of California, down from $36.1 million in the prior quarter.
  • Over five years, Common Equity peaked at $791.0 million in Q4 2021 and troughed at $5.3 million in Q4 2025.
  • A 5-year average of $475.3 million and a median of $562.9 million in 2022 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: surged 523.9% in 2021 and later tumbled 98.94% in 2025.
  • Year by year, Common Equity stood at $791.0 million in 2021, then fell by 28.84% to $562.9 million in 2022, then rose by 24.59% to $701.3 million in 2023, then decreased by 27.76% to $506.6 million in 2024, then tumbled by 98.94% to $5.3 million in 2025.
  • Business Quant data shows Common Equity for PACB at $5.3 million in Q4 2025, $36.1 million in Q3 2025, and $61.5 million in Q2 2025.